

Patent Application
Attorney Docket No. PC22013AADO

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Washington, D.C. 20231 on this 11th day of April, 2003.


By

Kelly A. Smith

(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: ALASDAIR M. NAYLOR, ET AL :

APPLICATION NO.: 10/017,273

: Examiner: San Ming Hui

FILING DATE: DECEMBER 12, 2001

: Group Art Unit: 1617

TITLE: TREATMENT OF MALE SEXUAL
DYSFUNCTION

Hon. Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

This is in reply to the Restriction Requirement mailed March 26, 2003
concerning the above-identified application.

REMARKS

Applicants request acknowledgment of the claim of foreign priority made in
the Declaration and Preliminary Amendment submitted with the application filing
papers.

Applicants have been required under 35 U.S.C. §121 to elect one of Groups
I-VII.

Pursuant to the request Applicants hereby elect Group I Claims 3-9, 13-16,
24, 33-38, and 44 drawn to a method of treating or preventing MED, classified in
class 514, subclass 184+.

The restriction requirement also required an election of species. The
restriction stated that the application claims are directed to the patentably distinct

species of the claimed invention in claims 34-37 and that there are a total of 37.

Applicants hereby elect the PDE inhibitors.

Applicants request an early examination and allowance of the application.

Respectfully submitted,

Date:

4/11/2003



A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4904